Lido Advisors’s Castle Biosciences CSTL Stock Holding History

Lido Advisors’s Portfolio CSTL Stock Details CSTL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$239K	Buy	10,034 +3	+0%	+$67	﹤0.01%	1863
2026 Q1	$246K	Sell	10,031 -5	-0%	-$164	﹤0.01%	1673
2025 Q4	$229K	Hold	10,036	–	–	﹤0.01%	1705
2025 Q3	$229K	Buy	10,036 +5	+0%	+$102	﹤0.01%	1625
2025 Q2	$205K	Hold	10,031	–	–	﹤0.01%	1513
2025 Q1	$201K	Sell	10,031 -493	-5%	-$12.2K	﹤0.01%	1389
2024 Q4	$280K	Hold	10,524	–	–	﹤0.01%	1237
2024 Q3	$300K	Hold	10,524	–	–	﹤0.01%	1168
2024 Q2	$229K	Hold	10,524	–	–	﹤0.01%	1237
2024 Q1	$233K	Hold	10,524	–	–	﹤0.01%	1206
2023 Q4	$227K	Buy	+10,524	New	+$185K	﹤0.01%	1156

Other funds holding CSTL

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Allianz Asset Management Munich, Germany $123B AUM 45.23% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

SPPAM

Summit Partners Public Asset Management Boston, Massachusetts $5.69B AUM 259.25% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Lido Advisors's CSTL Position: Q2 2026 in Review

Lido Advisors increased its Castle Biosciences (CSTL) stake by 0.03% in Q2 2026, buying an estimated $67 and bringing the position to 10,034 shares worth $239K. The position accounts for ﹤0.01% of the portfolio, ranked #1863.

Lido Advisors first reported a position in CSTL in Q4 2023 and has held it in 11 quarters since. The position peaked at $300K in Q3 2024. 177 funds tracked by Wall St. Rank hold CSTL as of Q2 2026.

Lido Advisors held 10,034 shares of Castle Biosciences worth $239K as of Q2 2026.
Lido Advisors bought 3 Castle Biosciences shares in Q2 2026, an estimated $67.
Castle Biosciences made up ﹤0.01% of Lido Advisors's portfolio in Q2 2026, its #1863 holding.
Lido Advisors first reported a position in Castle Biosciences in Q4 2023 and has held it in 11 quarters since.
Lido Advisors's Castle Biosciences position peaked at $300K in Q3 2024.
177 funds tracked by Wall St. Rank held Castle Biosciences as of Q2 2026.

Based on Lido Advisors's 13F filing for Q2 2026, filed 7 Aug 2026.